Status:
COMPLETED
Recombinant Human Erythropoietin Use in Intensive Care Unit (ICU) Patients: Does it Prevent Acute Renal Failure
Lead Sponsor:
University Hospital, Geneva
Conditions:
Acute Renal Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Pilot study aiming to assess the effect of two doses of rhu EPO on urine NGAL concentration and on serum cystatin C and creatinine levels in critically ill patients at risk of ARF.
Detailed Description
Research plan Open-label randomized trial Twelve months duration trial Setting: Medical and Surgical Intensive Care Unit of the University Hospitals of Geneva Start of trial: Mid-May 2008 Patients ra...
Eligibility Criteria
Inclusion
- Patients at risks for acute tubular necrosis (patients with mechanical ventilation, patients with sepsis, in the post-operative state, with hemodynamic impairment or with previous chronic renal failure.
- Consent form signed
Exclusion
- Patients with malignant hypertension
- Patients with systolic BP \> 150 mmHg at enrollment
- Patients with Hb level \> 120g/L
- Patients with acute coronaropathy
- Pregnancy
- Patients with urine output \< 600 ml/12 h
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00676234
Start Date
May 1 2008
End Date
June 1 2009
Last Update
June 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nephrology Unit, Geneva University Hospitals
Geneva, Canton of Geneva, Switzerland, 1211